The Global Avascular Necrosis Market, by Type (Trauma  Related  Avascular  Necrosis, and Non-Trauma  Related  Avascular  Necrosis), by Treatment (Drug-based and Surgery- based (Core Decompression Surgery, Osteotomy, Bone Graft, and Total Joint Replacement)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 512.9 million in 2017, and is projected to exhibit a CAGR of 6.0% over the forecast period (2018 - 2026).

 Avascular necrosis is a condition that results when blood flow to the head of thighbone is reduced or stopped, which leads to death of cells of bone tissue. There is no known pharmaceutical cure for permanent cure of avascular necrosis. Several combinations of non-operative treatments are used to reduce symptomatic pain such as electrical stimulation, hyperbaric oxygen therapy, shock wave therapy, physiotherapy, pharmaceuticals (such as bisphosphonates, anticoagulants, vasodilators, and lipid lowering agents), and muscle strengthening exercises.

Operative treatments for avascular necrosis include core decompression, osteotomies, bone and cartilage grafting, and total hip replacement surgery. Biopsy is a conclusive way to diagnose avascular necrosis but is rarely used as it requires surgery. Recovery and rehabilitation of avascular necrosis depends on surgical treatment used. For instance, core decompression usually requires patients to use crutches for several weeks, while the recovery period for a bone graft used in combination with decompression is much longer. Osteotomies limit activity for few months, however, a total hip replacement allows patients to begin walking with support, within days.

Browse 17 Market Data Tables and 21 Figures spread through 147 Pages and in-depth TOC on "Avascular Necrosis Market, by Type (Trauma Related Avascular Necrosis, Non-Trauma Related Avascular Necrosis), by Treatment (Drug Based, Surgery Based {Core Decompression Surgery, Osteotomy, Bone Graft, And Total Joint Replacement}), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"

To know the latest trends and insights related to avascular necrosis market, click the link below:

https://www.coherentmarketinsights.com/market-insight/avascular-necrosis-market-2218

Early diagnosis and treatment are essential for delaying disease progression and minimizing the need for costly and invasive procedures in avascular necrosis patients. According to Chinese Medical Journal 2015 study, direct cost to patients for undergoing primary total hip arthroplasty per hip without revision is between US$ 8000 and US$ 10,000 in China. Manufacturers in avascular necrosis market majorly focus on developing effective and inexpensive therapies for treating the disease. For instance, Bone Therapeutics and Enzo Biochem, Inc. focuses on gene regulation and cell-based product treatment, which is expected to increase avascular necrosis market revenue.

Key Takeaways of the Avascular Necrosis Market:

  • The global avascular necrosis market is expected to surge at a CAGR of 6.0% during the forecast period (2018–2026), owing to high prevalence of avascular necrosis coupled with the development of new therapies to treat the disease. According to the National Organization for Rare Disorders 2015 data, avascular necrosis is one of the rare diseases and affects one in 2000 people.
  • Among region, Asia Pacific is expected to witness the highest rate of growth during the forecast period, owing to high prevalence of non-traumatic avascular necrosis of femoral head. According to Clinical Orthopedics and Related Research, 2010, in Japan about 2500–3300 new cases of non-traumatic avascular necrosis of the femoral head are reported annually, while around 11,400 patients were found to have sought treatment in 2004.
  • Major players operating in the global avascular necrosis market include Bone Therapeutics, Boehringer Ingelheim GmbH, Bayer AG, Enzo Biochem Inc., Ethicon Inc., Eli Lilly and Company, Grifols SA, Integra LifeSciences Corporation, K-Stemcell Co Ltd., Medtronic Plc, Merck KGaA, Pfizer Inc., Sanofi SA, Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner